#Diabetes #Type2Diabetes #GLP1 #SGLT2 #MetabolicHealth #ClinicalTrials #DrugDevelopment #PharmaceuticalIndustry #HealthcareInnovation #Endocrinology #Obesity #FutureOfMedicine To view or add a comment, sign in More Relevant Posts Insulin Pharmacotherapy Across the Continuum of Care: Indications, Mechanisms, Adverse Effects, and Management ---- --- Dr Indunil Karunarathna Uva Clinical Research Lab 2026 Uva Clinical Anaesthesia and Intensive Care ISSN 2827-7198, 2026 Insulin remains an indispensable biologic agent in modern therapeutics, with its most critical applications centered on type 1 diabetes mellitus, advanced type 2 diabetes mellitus, gestational diabetes, and acute metabolic emergencies such as diabetic ketoacidosis and the hyperosmolar hyperglycemic state
Once you stop taking the medication, your appetite and hunger hormones rebound, leading to: A return of appetite and food cravings Reduced satiety (feelings of satisfaction/fullness)
Again, bear in mind that the choice between these medications often depends on individual patient factors, healthcare provider recommendations, and specific health goals
Lowering the cost of GLP-1s for people could have a significant impact on their health
For individuals with type 2 diabetes, low blood sugar levels (hypoglycemia) can be a concern when GLP-1 agonists are used in combination with other glucose-lowering medications, such as sulfonylureas or insulin
Studies show that approximately two-thirds of the weight lost on GLP-1 therapy is regained within one year of discontinuation if no other interventions are in place
